Newsroom

Sorted by: Latest
-

Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk

BOSTON--(BUSINESS WIRE)--Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification. Enrollment is underway at three of more than 20 planned sites across the U.S., Europe, and Asia: Emory University, the Medical University of South Carolina, and Centro Cardiologico Monzino, Milan, led...
-

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma....
-

AccurKardia and Wellysis Sign Multi-Year Agreement to Provide Wellysis’ Turnkey Cardiac Monitoring Offering in the U.S. Market

NEW YORK & SEOUL--(BUSINESS WIRE)--AccurKardia, Inc., an ECG-led diagnostics software company, and Wellysis, a digital healthcare company and developer of the S-Patch wearable ECG monitor, today announced a multi-year agreement under which AccurKardia’s AccurECG 2.0 will power the analytics behind Wellysis’ turnkey cardiac monitoring offering in the U.S. The agreement, which was signed last week in Seoul, is the latest between the two companies.Under the agreement, Wellysis’ S-Patch wearable dev...
-

Altasciences et Evidence Matters font progresser le développement de médicaments basé sur l'IA grâce à une avancée majeure en matière d'automatisation des essais précliniques

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, une organisation entièrement intégrée spécialisée dans le développement de médicaments en phase précoce, et Evidence Matters, pionnier dans le domaine de la science des données issues des essais cliniques, ont le plaisir d’annoncer la réussite d’une démonstration de concept (POC) de RegulatoryFlow (« RegFlow »), suite à l’annonce de leur collaboration stratégique en août 2025. Cette validation de principe a démontré que les gains d’efficacité généré...
-

Half of Gen Z Workers Report AI Guilt Despite Rising Demand for AI Skills

LONDON--(BUSINESS WIRE)--A new workplace trend is emerging for Gen Z employees: “AI Guilt”, where younger workers increasingly see AI literacy as essential to their careers, but do not yet feel they have clear permission for using it openly at work. New data from Employment Hero, the global AI-powered employment platform, reveals that 50% of Gen Z workers feel guilty using AI to produce work, while 52% say using AI to do parts of their job feels like cheating. The data forms part of Employment...
-

$150 Million in C-PACE Financing Identified to Fund Completion of Regent Bank Amphitheater and Sunset Amphitheater at McKinney

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation ("VENU" or the "Company") (NYSE AMERICAN: VENU), owner, operator, and developer of premium live entertainment destinations, today announced that CBRE Group Inc. (NYSE: CBRE), retained by the Company to secure Commercial Property Assessed Clean Energy ("C-PACE") financing, has identified more than $150 million in gross proceeds for VENU®. C-PACE proceeds are expected to fully fund the balance of construction for Regent Bank Amphi...
-

IS $9.50 PER SHARE FAIR FOR GBTG SHAREHOLDERS? Kaskela Law is Investigating the Looming Shareholder Buyout and Encourages Investors to Contact the Firm Today to Discuss their Rights and Options

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Investor protection law firm Kaskela Law is investigating the Global Business Travel Group, Inc. (NYSE: GBTG) (“GBTG”) shareholder buyout to determine whether the transaction as structured is fair and provides investors with a sufficient price for their GBTG shares. Click here for additional information: https://kaskelalaw.com/case/global-business-travel-group/ On May 4, 2026, GBTG announced that it had agreed to be privatized at a price of $9.50 per share...
-

Three New Independent Members Join Orano Med’s Governing Board

VILLEJUIF, France--(BUSINESS WIRE)--Orano Med has appointed Caroline Germa, Jean-Pierre Bizzari and Philippe Archinard as independent members of the Governing Board....
-

50 ans d’engagement du Canada envers le patrimoine mondial : la Fiducie nationale du Canada invite tout le pays à célébrer

OTTAWA, Canada--(BUSINESS WIRE)--La Fiducie nationale du Canada, le principal organisme de bienfaisance du pays voué à la protection et à la promotion des lieux patrimoniaux, souligne le 50e anniversaire de l’adhésion du Canada à la Convention du patrimoine mondial de l’UNESCO en lançant une série d’événements partout au pays. Les célébrations auront lieu dans trois lieux du patrimoine mondial au Canada : le Canal Rideau à Ottawa le 23 juillet, Le Vieux Lunenburg en Nouvelle-Écosse le 25 juille...
-

Trois nouveaux membres indépendants rejoignent le Conseil de gouvernance d’Orano Med

VILLEJUIF, France--(BUSINESS WIRE)--Orano Med, filiale du groupe Orano spécialisée en médecine nucléaire, annonce la nomination de Caroline Germa, Jean-Pierre Bizzari et Philippe Archinard en qualité de membres indépendants du Conseil de gouvernance dédié aux activités de biotechnologie de la filiale. Ils exerceront leurs fonctions aux côtés de Fabrice Chouraqui, membre du Conseil de gouvernance depuis 2022, et dont le mandat se poursuit. Ces trois nouveaux membres apportent au Conseil une expe...